Lowest Price Guaranteed
From USD
4,899
Published
January 2020
Pages
554
View Count
1094
, 2019-2030-Context.PNG) |
,%202019-2030-List%20of%20syringes%20manufacturers.png) |
, 2019-2030-Combination Products.PNG) |
, 2019-2030-Product Competitiveness analysis.PNG) |
, 2019-2030-Fill Finish Service providers.PNG) |
, 2019-2030-Big pharma initiatives.PNG) |
, 2019-2030-Pipeline.PNG) |
, 2019-2030-Market Forecast.PNG) |
, 2019-2030-Futuer Forecast.PNG) |
We are seeing an increased demand in the emerging markets, particularly within the BRICS nations, namely Brazil, Russia, India, China and South Africa. North Africa and the Middle East also present a similar scenario, characterized by a growth rate of 10-18% for prefilled syringes
-- Marketing Director, a large-sized company
According to experts in the healthcare industry, one in three adults are estimated to be suffering from some type of chronic clinical condition, such as multiple sclerosis, diabetes, rheumatoid arthritis and cardiovascular diseases. Chronic clinical conditions are considered to be among the leading causes of death and disability across the world. Typically, in such cases, individuals are required to medicate on a daily basis. In addition to the cost of medication, such individuals are also burdened with a deteriorating quality of life, and often struggle with medication adherence. According to the US Centers for Disease Control (CDC), the overall annual expense incurred by those living with chronic diseases is steadily growing and is currently estimated to be more than USD 3 trillion. The development and commercialization of self-administrable dosage forms of drugs indicated to treat chronic clinical conditions has made a significant positive impact not only on the healthcare expenses borne by patients but also on compliance to prescribed therapeutic regimens. As the number of patients suffering from such disorders increase, the demand for more convenient and patient friendly drug delivery solutions is also on the rise.
Most self-injection devices / systems, such as autoinjectors and pen-injectors, rely on prefilled syringes, which serve as primary drug containers in the aforementioned products. Moreover, despite having been in the market for more than three decades now, the overall interest in prefilled syringes continues to grow. In fact, the recent increase in use of biologics, which are usually administered via parenteral routes, has had a significant impact on the demand for prefilled syringes. Over the years, significant improvements have been made to conventional prefilled syringes in order to further expand the scope of their applications. In this context, it is worth mentioning that dual / multi chambered syringes designed for the administration of lyophilized drugs are already available in the market. In such products, the syringe barrel is divided into two chambers, one of which contains the appropriate diluent for the prefilled (lyophilized) drug formulation. Likewise, there are multiple types of specialty syringes, including contrast agent containing syringes and flush syringes. Further, since the introduction and enforcement of the Needlestick Safety and Prevention Act in 2000, several medical device manufactures have developed add-on or integrated safety devices for prefilled syringes. In fact, by 2020, the incorporation of safety features in prefilled syringes is anticipated to be made mandatory across the world. We are led to believe that the aforementioned developments are likely to fuel innovation and subsequent future growth in this market.
The ‘Prefilled Syringes Market (5th edition), 2019-2030’ report features an extensive study of the current market landscape of prefilled syringes and the likely future opportunities associated with such devices, over the next 10-12 years. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to evaluate the current market size and the future opportunity within the prefilled syringes market. Based on various relevant parameters, such as the number of commercialized combination products, annual adoption rate, and expected pricing, we have provided an informed estimate of the likely evolution of the market over the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] therapeutic area (blood disorders, infectious diseases, metabolic disorders, autoimmune disorders, oncology disorders, neurological disorders, ophthalmic diseases and others), [B] type of syringe, [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber), [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)).
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the prefilled syringes market in the mid to long term.
Chapter 3 provides an introduction to the concept of prefilled syringes, including details on their origin, various affiliated components (such as barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap), fabrication material (glass and plastic), manufacturing-related information, and other critical attributes and features. In addition, the chapter includes a discussion highlighting the future of prefilled syringes.
Chapter 4 provides an overview of around 80 prefilled syringes that are available in the market and provides details on the companies that manufacture such products. It features analyses of the prefilled syringes, based on various parameters, such as type of material (glass and plastic), number of barrel chambers (dual chamber and single chamber), type of needle system (fixed needle system and luer lock system) and syringe volume. In addition, the chapter provides information on manufacturers, along with information on year of establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes a discussion on the technological advances of prefilled syringes that have taken place in the recent past.
Chapter 5 presents a product competitiveness analysis of glass and plastic prefilled syringes (separately) based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
Chapter 6 includes detailed profiles of some of the key manufacturers of prefilled syringes based in different geographies. Each profile includes a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook. In addition, the chapter also features short profiles of some of the small and mid-sized manufacturers, highlighting brief overview of the company, product portfolio and recent developments (if available).
Chapter 7 highlights the growing concerns associated with needlestick injuries and the various steps (including regional and global legislations) that have been taken to prevent sharps related mishaps. One of the important risk mitigation strategies covered in this chapter is the installation of safety features in upcoming versions of prefilled syringes. In addition, the chapter provides information on syringe-related safety systems, including both add-on devices and device integrated features, and the companies involved in developing and manufacturing such solutions.
Chapter 8 presents overview of the regulatory environment related to the grant of marketing authorizations for combination products across different countries. It highlights the prefilled syringes regulatory requirements and the role of regulatory bodies in the approval of syringes in North America, Europe, Latin America, Asia Pacific and the Middle East.
Chapter 9 provides details on the various pipeline and approved products that are being tested or available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. It features a detailed analysis of these drugs, based on the various parameters, such as the target therapeutic area(s), phase of development, type of drug molecule, route of administration, approval year (in case of marketed products), dosage (in case of marketed products) and other approved dosage forms (in case of marketed products). In addition, the chapter provides information on drug developers, year of their establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes case studies of top two marketed drugs available in prefilled syringes, namely Humira® and Enbrel®.
Chapter 10 features a discussion on the most commonly targeted therapeutic indications, including information on the approved / marketed injectable drug products available for the treatment of such clinical conditions (across different target therapeutic areas) and their respective biosimilars.
Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via prefilled syringes in the future. It is worth highlighting that this list has been compiled based on various parameters, such as route of administration, target therapeutic indication(s), other available dosage forms (in case of marketed drugs), type of drug molecule and drug sales of the approved product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a prefilled syringe in the future was estimated using the weighted average method. Additionally, the chapter features an insightful analysis, highlighting potential strategic partners (primarily drug developers) for prefilled syringes manufacturers, based on multiple parameters, such as pipeline strength, targeted therapeutic indications, and developer strength. The analysis aims to provide the necessary inputs to the latter type of stakeholders, enabling them to make the right decisions to develop combination products.
Chapter 12 highlights top ten big pharma players engaged or likely to be engaged in the domain of prefilled syringes. It features a benchmarking of the companies based on parameters, such as current adoption (based on number of approved and development-stage prefilled syringe combination products) and likely future adoption (based on potential likely early and late stage pipelines), target therapeutic area(s), and type of drug molecules.
Chapter 13 features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and prefilled contrast agent delivery systems. For each type of specialty syringe, we have provided a brief overview and details on the different products that are available in the market and their advantages.
Chapter 14 discusses the recent technological developments in this domain and their applications. The chapter provides details on the advancements in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual chambered syringe systems. The chapter also highlights novel lubrication and sterilization technologies.
Chapter 15 presents an insightful market forecast analysis, highlighting the future potential of the prefilled syringes market till the year 2030. We have segregated the opportunity of the market on the basis of [A] therapeutic area (blood disorders, infectious diseases, metabolic disorders, autoimmune disorders, oncology disorders, neurological disorders, ophthalmic diseases and others), [B] type of syringe, [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber), [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)). The analysis presents 2 X 2 matrices based on Market Share and Market Attractiveness derived from the current and likely future state of the market.
Chapter 16 features a detailed discussion on the various factors that are anticipated to drive growth within the prefilled syringes market, such as the rise in preference for self-administration of medication, increase in incidence of chronic diseases, evolving patient landscape, introduction and growing adoption of biologics / biosimilars, initiatives focused on the prevention of needlestick injuries and the various potential applications of prefilled syringes.
Chapter 17 provides a detailed SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.
Chapter 18 provides insights on the various prefilled syringe component manufacturers along with details of their respective product portfolios. The key players covered in this section include Aptar Stelmi, Datwyler, Lonstroff, Ompi, West Pharmaceutical and Jiangsu Hualan New Pharmaceutical Material.
Chapter 19 provides an overview of the landscape of pharmaceutical companies that offer fill / finish contract services for prefilled syringes. It includes information related to around 45 contract service providers that are currently active in this domain. It features in-depth analyses based on a number of relevant parameters, such as scale of operation (preclinical, clinical and commercial), type of drug molecules filled (small molecule and biologics), year of establishment, company size and geographical location of the service providers.
Chapter 20 presents a list of autoinjectors that utilize prefilled syringes as their primary containers. In this chapter, we have included profiles of manufacturers of such autoinjectors, featuring an overview of the company and respective product portfolios. The key players that have been covered in this section include Elcam Medical, Nuance Designs, Owen Mumford, SHL Group, Union Medico and Ypsomed.
Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 22 is a collection of transcripts of interviews conducted with representatives from renowned organizations that are engaged in the prefilled syringes manufacturing domain. In this chapter, we have presented the details of our conversations with Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical), Marco Pederiva (Marketing & Sales Director, Lonstroff) and Anonymous (Chief Executive Officer, Small-sized Medical Device Company).
Chapters 23 is an appendix that provides tabulated data and numbers for all the figures included in the report.
Chapter 24 is an appendix that contains the list of companies and organizations mentioned in the report.
1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2 EXECUTIVE SUMMARY
3 INTRODUCTION TO PREFILLED SYRINGES
3.1. Chapter Overview
3.2. Evolution of Prefilled Syringes
3.3. Benefits of Prefilled Syringes
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits to Manufacturers
3.3.3. Shift from Existing Dosage Forms to Prefilled Syringes
3.4. Prefilled Syringe Components
3.5. Classification of Prefilled Syringes
3.5.1. Classification by Barrel Fabrication Material
3.5.1.1. Glass
3.5.1.1.1. Limitations of Glass Barrel Prefilled Syringes
3.5.1.1.2. Addressing the Limitations of Glass Barrel Prefilled Syringes
3.5.1.2. Plastic
3.5.1.2.1. Limitations of Plastic Barrel Prefilled Syringes
3.5.1.2.2. Addressing the Limitations of Plastic Barrel Prefilled Syringes
3.5.1.2.3. Factors Likely to Drive the Use of Plastic Barrel Prefilled Syringes
3.5.2. Classification by Number of Chambers in the Barrel
3.5.3. Classification by Type of Needle System
3.5.4. Classification by Type of Packaging
3.6. Critical Attributes of Prefilled Syringe Design
3.7. Manufacturing Prefilled Syringes
3.7.1. Production of Barrels
3.7.1.1. Glass Barrel Prefilled Syringes
3.7.1.2. Plastic Barrel Prefilled Syringes
3.7.2. Production of Syringes
3.7.3. Barrel Siliconization
3.7.4. Syringe Sterilization
3.7.5. Validation of Sterilization
3.7.6. Syringe Filling
3.7.7. Syringe Testing
3.8. Future of Prefilled Syringes
4 PREFILLED SYRINGES: MARKET OVERVIEW
4.1. Chapter Overview
4.2. Prefilled Syringes: List of Available / Under Development Devices
4.2.1. Analysis by Type of Barrel Fabrication Material
4.2.2. Analysis by Number of Barrel Chambers
4.2.3. Analysis by Type of Needle System
4.2.4. Analysis by Device Capacity
4.3. Prefilled Syringes: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geographical Location of Headquarters
4.3.4. Analysis by Geographical Location of Manufacturing Facilities
4.4. Technological Developments in Prefilled Syringes
5 PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Product Competitiveness Analysis
5.4.1. Glass Barrel Prefilled Syringes
5.4.2. Plastic Barrel Prefilled Syringes
6 MANUFACTURERS OF PREFILLED SYRINGES
6.1. Chapter Overview
6.2. Key Prefilled Syringe Manufacturers Based in North America
6.2.1. Becton Dickinson
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Prefilled Technology Solutions
6.2.1.4. Glass Barrel Prefilled Systems
6.2.1.4.1. BD Hypak Prefilled Syringe
6.2.1.4.2. BD Neopak Prefilled Syringe
6.2.1.4.3. BD Hylok Prefilled Syringe
6.2.1.5. Plastic Barrel Prefilled Systems
6.2.1.5.1. BD Sterifill Syringe Systems
6.2.1.6. Other Prefilled Delivery Systems
6.2.1.6.1. BD Uniject
6.2.1.7. Recent Developments
6.2.1.8. Future Outlook
6.2.2. West Pharmaceutical
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Prefilled Technology Solutions
6.2.2.4. Plastic Barrel Prefilled Systems
6.2.2.4.1. Daikyo Crystal Zenith Polymer RTU Prefilled Syringe
6.2.2.5. Drug Reconstitution Systems
6.2.2.6. Recent Developments
6.2.2.7. Future Outlook
6.3. Key Prefilled Syringe Manufacturers Based in Europe
6.3.1. Gerresheimer
6.3.1.1. Company Overview
6.3.1.2. Financial Performance
6.3.1.3. Prefilled Technology Solutions
6.3.1.4. Glass Barrel Prefilled Systems
6.3.1.4.1. Gx Glass Syringes
6.3.1.5. Plastic Barrel Prefilled Systems
6.3.1.5.1. ClearJect Prefilled syringes
6.3.1.5.2. Gx RTF Clearject Needle Syringe
6.3.1.6. Safety Syringes
6.3.1.6.1. Gx InnoSafe Safety Syringes
6.3.1.7. Self-Injection Devices
6.3.1.8. Recent Developments
6.3.1.9. Future Outlook
6.3.2. Ompi
6.3.2.1. Company Overview
6.3.2.2. Financial Performance
6.3.2.3. Glass Barrel Prefilled Systems
6.3.2.3.1. EZ-Fill Syringes
6.3.2.3.1.1. EZ-fill Fina
6.3.2.3.1.2. EZ-fill Nexa
6.3.2.3.1.3. EZ-fill Alba
6.3.2.4. Recent Developments
6.3.2.5. Future Outlook
6.3.3. SCHOTT
6.3.3.1. Company Overview
6.3.3.2. Financial Performance
6.3.3.3. Glass Barrel Prefilled Syringes
6.3.3.3.1. syriQ Glass Syringes
6.3.3.4. Plastic Barrel Prefilled Syringes
6.3.3.4.1. TopPac Polymer Syringes
6.3.3.5. Recent Developments
6.3.3.6. Future Outlook
6.4. Key Prefilled Syringe Manufacturers in Asia
6.4.1. Nipro Corporation (Acquired MGlas)
6.4.1.1. Company Overview
6.4.1.2. Financial Performance
6.4.1.3. Glass Barrel Prefilled Systems
6.4.1.4. Recent Developments
6.4.1.5. Future Outlook
6.4.2. WEGO Prefills Pharmaceutical Packaging
6.4.2.1. Company Overview
6.4.2.2. Financial Performance
6.4.2.3. WeGo Glass Prefilled Syringe
6.4.2.4. Weigao Prefilled Flush Syringes
6.4.2.5. Future Outlook
6.4.3. Taisei Kako
6.4.3.1. Company Overview
6.4.3.2. Glass Barrel Prefilled Systems
6.4.3.2.1. VF-Syringe
6.4.3.2.1. SIN-Syringe
6.4.3.3. Plastic Barrel Prefilled System
6.4.3.3.1. ClearJect Syringes
6.4.3.3.2. FULJECT Passive Type Syringe
6.4.3.3.3. Ajex Needleless Injection System
6.4.3.4. Future Outlook
6.4.4. Terumo Corporation
6.4.4.1. Company Overview
6.4.4.2. Financial Performance
6.4.4.3. Plastic Barrel Prefilled Syringe
6.4.4.4. Safety Devices: Add-On Devices
6.4.4.5. Recent Developments
6.4.4.6. Future Outlook
6.5. Other Manufacturers
6.5.1. Aguettant
6.5.1.1. Company Overview
6.5.1.2. Prefilled Syringe Portfolio
6.5.1.2.1. Aguettant Prefilled Syringe
6.5.1.3. Recent Developments
6.5.2. Arte Corporation
6.5.2.1. Company Overview
6.5.2.2. Prefilled Syringe Portfolio
6.5.2.2.1. Dual Chamber Prefillable Syringe
6.5.2.2.2. Single Chamber Prefillable Syringe
6.5.3. J.O. Pharma (Subsidiary of Otsuka Holdings)
6.5.3.1. Company Overview
6.5.3.2. Prefilled Syringe Portfolio
6.5.4. Pfizer Injectables
6.5.4.1. Company Overview
6.5.4.2. Prefilled Syringe Portfolio
6.5.4.2.1. ABBOJECT Syringe
6.5.4.2.2. Emergency Syringes
6.5.4.2.3. iSecure Syringe System
6.5.5. Shandong Pharmaceutical Glass
6.5.5.1. Company Overview
6.5.5.2. Prefilled Syringe Portfolio
6.5.6. Shandong Zibo Minkang Pharmaceutical packing
6.5.6.1. Company Overview
6.5.6.2. Prefilled Syringe Portfolio
6.5.7. Vetter Pharma
6.5.7.1. Company Overview
6.5.7.2. Prefilled Syringe Portfolio
6.5.7.2.1. Lyo-Ject Glass Prefilled Syringe
6.5.7.2.2. Vetter-Ject Safety Device
6.5.7.2.3. V-OVS Safety Device
6.5.7.3. Recent Developments
6.5.8. Yangzhong Wealth Metal
6.5.8.1. Company Overview
6.5.8.2. Prefilled Syringe Portfolio
7 NEEDLESTICK INJURIES
7.1. Chapter Overview
7.2. Incidence and Associated Financial Burden
7.3. Government Legislations for Prevention of Needlestick Injuries
7.4. Safety Mechanisms Used in Modern Prefilled Syringes
7.4.1. Safety Systems: Add-On Safety Device Manufacturers
7.4.1.1. Becton Dickinson
7.4.1.2. Catalent
7.4.1.3. Terumo
7.4.1.4. Tip-Top
7.4.1.5. West Pharmaceutical
7.4.2. Safety Systems: Integrated Safety Device Manufacturers
7.4.2.1. Gerresheimer
7.4.2.2. Injecto
7.4.2.3. MedicalChain International
7.4.2.4. OMPI
7.4.2.5. Owen Mumford
7.4.2.6. Retractable Technologies
7.4.2.7. SHL Group
7.4.2.8. Taisei Kako
8 REGULATORY LANDSCAPE FOR PREFILLED SYRINGES
8.1. Chapter Overview
8.2. Regulatory Approval of Combination Products in the US
8.2.1. Overview
8.2.2. Regulatory Bodies and their Role in Product Approval
8.2.3. Regulatory Approval for Prefilled Syringes
8.3. Regulatory Approval of Combination Products in Europe
8.3.1. Overview
8.3.2. Regulatory Bodies and their Role in Product Approval
8.3.3. Regulatory Approval for Prefilled Syringes
8.4. Regulatory Approval of Combination Products in Canada
8.4.1. Overview
8.4.2. Regulatory Bodies and their Role in Product Approval
8.4.3. Regulatory Approval for Prefilled Syringes
8.5. Regulatory Approval of Combination Products in Brazil
8.5.1. Overview
8.5.2. Regulatory Bodies and their Role in Product Approval
8.5.3. Regulatory Approval for Prefilled Syringes
8.6. Regulatory Approval of Combination Products in Mexico
8.6.1. Overview
8.6.2. Regulatory Bodies and their Role in Product Approval
8.6.3. Regulatory Approval for Prefilled Syringes
8.7. Regulatory Approval of Combination Products in Argentina
8.7.1. Overview
8.7.2. Regulatory Bodies and their Role in Product Approval
8.7.3. Regulatory Approval for Prefilled Syringes
8.8. Regulatory Approval of Combination Products in Australia
8.8.1. Overview
8.8.2. Regulatory Bodies and their Role in Product Approval
8.8.3. Regulatory Approval for Prefilled Syringes
8.9. Regulatory Approval of Combination Products in Japan
8.9.1. Overview
8.9.2. Regulatory Bodies and their Role in Product Approval
8.9.3. Regulatory Approval for Prefilled syringes
8.10. Regulatory Approval of Combination Products in China
8.10.1. Overview
8.10.2. Regulatory Bodies and their Role in Product Approval
8.10.3. Regulatory Approval for Prefilled syringes
8.11. Regulatory Approval of Combination Products in India
8.11.1. Overview
8.11.2. Regulatory Bodies and their Role in Product Approval
8.11.3. Regulatory Approval for Prefilled Syringes
8.12. Regulatory Approval of Combination Products in South Korea
8.12.1. Overview
8.12.2. Regulatory Bodies and their Role in Product Approval
8.12.3. Regulatory Approval for Prefilled Syringes
8.13. Regulatory Approval of Combination Products in Saudi Arabia
8.13.1. Overview
8.13.2. Regulatory Bodies and their Role in Product Approval
8.14. Regulatory Approval for Prefilled Syringes
8.15. Regulatory Approval of Combination Products in United Arab Emirates
8.15.1. Overview
8.15.2. Regulatory Bodies and their Role in Product Approval
8.15.3. Regulatory Approval for Prefilled Syringes
9. PREFILLED SYRINGE COMBINATION PRODUCTS: MARKET OVERVIEW
9.1. Chapter Overview
9.2. Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2019
9.2.1. Analysis by Type of Drug Molecule
9.2.2. Analysis by Approval Year
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Target Therapeutic Area
9.2.5. Prefilled Syringe Combination Products: Additional Information
9.2.5.1. Analysis by Dose Strength
9.2.5.2. Analysis by Other Approved Dosage Forms
9.3. Prefilled Syringe Combination Products: List of Pipeline Drugs, 2013-2019
9.3.1. Analysis by Type of Drug Molecule
9.3.2. Analysis by Phase of Development
9.3.3. Analysis by Route of Administration
9.3.4. Analysis by Target Therapeutic Area
9.3. Prefilled Syringe Combination Products: List of Developers
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Geographical Location of Headquarters
9.4. Popular Drugs in Prefilled Syringes: Case Studies
9.4.1. HUMIRA® (Adalimumab), AbbVie / Eisai
9.4.1.1. Target Indications and Available Dosage Forms
9.4.1.2. Shift from Vials to Syringes
9.4.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda
9.4.2.1. Target Indications and Available Dosage Forms
9.4.2.2. Shift from Vials to Syringes
10 KEY THERAPEUTIC AREAS
10.1. Chapter Overview
10.1.1. Autoimmune Disorders
10.1.1.1. Approved Injectables
10.1.1.2. Biosimilars
10.1.2. Infectious Diseases
10.1.2.1. Antiviral Drugs
10.1.2.1.1. Approved Injectables
10.1.2.1.2. Biosimilars
10.1.2.2. Vaccines
10.1.2.2.1. Approved Injectables
10.1.3. Neurological Disorders
10.1.3.1. Approved Injectables
10.1.3.2. Biosimilars
10.1.4. Metabolic Disorders
10.1.4.1. Approved Injectables
10.1.4.2. Biosimilars
11 PREFILLED SYRINGES LIKELY DRUG CANDIDATES AND PARTNER ANALYSIS
11.1. Chapter Overview
11.2. Marketed Drug Candidates
11.2.1. Most Likely Candidates for Delivery via Prefilled Syringes
11.1.2. Likely Candidates for Delivery via Prefilled Syringes
11.2.3. Less Likely Candidates for Delivery via Prefilled Syringes
11.2.4. Unlikely Candidates for Delivery via Prefilled Syringes
11.3. Clinical Drug Candidates
11.3.1. Most Likely Candidates for Delivery via Prefilled Syringes
11.3.2. Likely Candidates for Delivery via Prefilled Syringes
11.3.3. Less Likely Candidates for Delivery via Prefilled Syringes
11.3.4. Unlikely Candidates for Delivery via Prefilled Syringes
11.4. Potential Strategic Partners
11.4.1. Opportunities in North America
11.4.1.1. Most Likely Partners for Prefilled Syringes Combination Product Development
11.4.1.2. Likely Partners for Prefilled Syringes Combination Product Development
11.4.1.3. Less Likely Partners for Prefilled Syringes Combination Product Development
11.4.1.4. Unlikely Partners for Prefilled Syringes Combination Product Development
11.4.2. Opportunities in Europe
11.4.2.1. Most Likely Partners for Prefilled Syringes Combination Product Development
11.4.2.2. Likely Partners for Prefilled Syringes Combination Product Development
11.4.2.3. Less Likely Partners for Prefilled Syringes Combination Product Development
11.4.2.4. Unlikely Partners for Prefilled Syringes Combination Product Development
11.4.3. Opportunities in Asia-Pacific and Rest of the World
11.4.3.1. Most Likely Partners for Prefilled Syringes Combination Product Development
11.4.3.2. Likely Partners for Prefilled Syringes Combination Product Development
11.4.3.3. Less Likely Partners for Prefilled Syringes Combination Product Development
11.4.3.4. Unlikely Partners for Prefilled Syringes Combination Product Development
12 BIG PHARMA INITIATIVES: PREFILLED SYRINGE COMBINATION PRODUCTS AND LIKELY CANDIDATES
12.1. Chapter Overview
12.2. Top Pharmaceutical Companies
12.2.1. Analysis by Therapeutic Area
12.2.1.1. Autoimmune Disorders
12.2.1.2. Infectious Diseases
12.2.1.3. Oncological Disorders
12.2.1.4. Metabolic Disorders
12.2.1.5. Neurological Disorders
12.2.1.6. Inflammatory Disorders
12.2.1.7. Orthopedic Disorders
12.2.1.8. Others
12.2.2. Analysis by Type of Molecule
12.2.2.1. Antibodies
12.2.2.2. Vaccines
12.2.2.3. Proteins
12.2.2.4. Others
13 SPECIALTY PREFILLED SYRINGES
13.1. Chapter Overview
13.2. Prefilled Flush Syringes
13.2.1. Overview
13.2.2. Prefilled Flush Syringes Available in the Market
13.2.3. Advantages of Prefilled Flush Syringes
13.3. Prefilled Diluent Syringes
13.3.1. Overview
13.3.2. Drugs Available in Prefilled Diluent Syringes
13.3.3. Advantages of Prefilled Diluent Syringes
13.4. Contrast Agent Prefilled Syringes
13.4.1. Overview
13.4.2. Contrast Agents Available in Prefilled Syringes
13.4.3. Advantages of Contrast Agent Prefilled Syringes
14 RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLED SYRINGES
14.1. Chapter Overview
14.2. Prefilled Syringes For Lyophilized Drugs
14.2.1. Prefilled Diluent Syringes
14.2.2. Prefilled Dual / Multi-Chamber Prefilled Syringes
14.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringes
14.2.2.2. Prefilled Dual-Chambered Prefilled Pen Injectors for Lyophilized Drugs
14.3. Prefilled Syringes for Ophthalmic Delivery
14.4. Prefilled Syringes for Dermal Fillers
14.5. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
14.6. Prefilled Syringes with Low Particle Formation Risk
14.7. Lubrication Technology for Prefilled Syringes
14.8. Advances in Terminal Sterilization of Prefilled Syringes
14.8.1. Noxilizer’s Nitrogen Dioxide Sterilization Technology
14.9. Development of Demonstrators for Prefilled Syringes
15 MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Global Prefilled Syringes Market, 2019-2030
15.3.1. Prefilled Syringes Market: Distribution by Therapeutic Area
15.3.1.1. Prefilled Syringes Market: Autoimmune Disorders
15.3.1.2. Prefilled Syringes Market: Infectious Diseases
15.3.1.3. Prefilled Syringes Market: Neurological Disorders
15.3.1.4. Prefilled Syringes Market: Oncologic Disorders
15.3.1.5. Prefilled Syringes Market: Ophthalmic Diseases
15.3.1.6. Prefilled Syringes Market: Other Diseases
15.3.2. Prefilled Syringes Market: Distribution by Specialty Syringes
15.3.3. Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material
15.3.3.1. Prefilled Syringes Market: Glass Barrel Syringes
15.3.3.2. Prefilled Syringes Market: Plastic Barrel Syringes
15.3.4. Prefilled Syringes Market: Distribution by Type of Chamber System
15.3.4.1. Prefilled Syringes Market: Single Chamber Syringes
15.3.4.2. Prefilled Syringes Market: Dual Chamber Syringes
15.3.5. Prefilled Syringes Market: Type of Drug Molecule
15.3.5.1. Prefilled Syringes Market: Antibodies
15.3.5.2. Prefilled Syringes Market: Proteins
15.3.5.3. Prefilled Syringes Market: Peptides
15.3.5.4. Prefilled Syringes Market: Small Molecule
15.3.5.5. Prefilled Syringes Market: Vaccines
15.3.6. Prefilled Syringes Market: Distribution by Geography
15.3.6.1. Prefilled Syringes Market: North America
15.3.6.2. Prefilled Syringes Market: Europe
15.3.6.3. Prefilled Syringes Market: Latin America
15.3.6.4. Prefilled Syringes Market: Asia-Pacific
15.3.6.5. Prefilled Syringes Market: Middle East and Africa
16 GROWTH DRIVERS
16.1. Chapter Overview
16.2. Growing Preference for Self-Injection
16.3. Rising Incidence of Chronic Diseases
16.4. Evolving Patient Demographics
16.5. Growth of Biologics and Biosimilars Market
16.6. Changing Pharmaceutical Strategies
16.7. Increasing Focus on Prevention of Needlestick Injuries
16.8. Prefilled Syringes in Autoinjectors and Pen Injectors
17 SWOT ANALYSIS
17.1. Chapter Overview
17.2. Strengths
17.3. Weaknesses
17.4. Opportunities
17.5. Threats
17.6. Concluding Remarks
18 PREFILLED SYRINGE COMPONENT MANUFACTURERS
18.1. Chapter Overview
18.2. List of Component Manufacturers
18.3. Aptar Pharma (a Part of AptarGroup)
18.3.1. Company Overview
18.3.2. Financial Performance
18.3.3. Product Portfolio
18.3.4. Recent Developments and Future Outlook
18.4. West Pharmaceutical
18.4.1. Company Overview
18.4.2. Financial Performance
18.4.3. Product Portfolio
18.4.4. Recent Developments and Future Outlook
18.5. Datwyler Sealing Solutions (a Part of Datwyler Group)
18.5.1. Company Overview
18.5.2. Financial Performance
18.5.3. Product Portfolio
18.5.4. Recent Developments and Future Outlook
18.6. Lonstroff (a Part of Sumitomo Rubber Industries)
18.6.1. Company Overview
18.6.2. Financial Performance
18.6.3. Product Portfolio
18.6.4. Recent Developments and Future Outlook
18.7. Ompi (a Part of Stevanato Group)
18.7.1. Company Overview
18.7.2. Product Portfolio
18.7.3. Recent Developments and Future Outlook
18.8. Jiangsu Hualan Pharmaceutical New Material
18.8.1. Company Overview
18.8.2. Product Portfolio
18.8.3. Recent Developments and Future Outlook
19 FILL-FINISH SERVICE PROVIDERS FOR PREFILLED SYRINGES
19.1. Chapter Overview
19.2. Fill-Finish Processing of Prefilled Syringes
19.2.1. Steps Involved in Fill-Finish Process
19.2.2. Methods of Filling and Stoppering of Prefilled Syringes
19.2.3. Prefilled Syringe Filling Technologies
19.3. Outsourcing of Fill-Finish Operations
19.4. Growth Considerations
19.5. Prefilled Syringes: List of Fill-Finish Service Providers
19.5.1. Analysis by Year of Establishment
19.5.2. Analysis by Scale of Operation
19.5.3. Analysis by Geographical Location of Headquarters and Type of Drug Molecule
20 CASE STUDY: AUTOINJECTORS
20.1. Chapter Overview
20.2. Autoinjectors: Market Overview
20.3. Key Players
20.3.1. Elcam Medical (E3D Elcam Drug Delivery Devices)
20.3.3.1. Company Overview
20.3.3.2. Product Portfolio
20.3.2. Nuance Designs
20.3.2.1. Company Overview
20.3.2.2. Product Portfolio
20.3.3. Owen Mumford
20.3.3.1. Company Overview
20.3.3.2. Product Portfolio
20.3.4. Scandinavian Health Limited (SHL) Group
20.3.4.1. Company Overview
20.3.4.2. Product Portfolio
20.3.5. Union Medico
20.3.5.1. Company Overview
20.3.5.2. Product Portfolio
20.3.6. Ypsomed
20.3.6.1. Company Overview
20.3.6.2. Product Portfolio
21 CONCLUDING REMARKS
21.1. Chapter Overview
21.2. Key Takeaways
22 INTERVIEW TRANSCRIPTS
22.1. Chapter Overview
22.2. Oval Medical Technologies
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Matthew Young, Founder and Chief Technology Officer
22.3. Intas Pharmaceuticals
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Kirti Maheshwari, Chief Technical Officer
22.4. IDT Biologika
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer
22.5. West Pharmaceutical
22.5.1. Company Snapshot
22.5.2. Interview Transcript: Kevin Cancelliere and Tibor Hlobik, Marketing Directors
22.6. Lonstroff
22.6.1. Company Snapshot
22.6.2. Interview Transcript: Marco Pederiva, Marketing and Sales Directors
22.7. Small-sized Medical Device Company
22.7.1. Interview Transcript: Anonymous, Chief Executive Officer
23 APPENDIX 1: TABULATED DATA
24 APPENDIX 2: LIST OF COMPANIES
Figure 3.1 Glass Barrel Prefilled Syringes: Advantages and Disadvantages
Figure 3.2 Properties of Cyclic Olefin Copolymer and Cyclo Olefin Polymer
Figure 3.3 Plastic Barrel Prefilled Syringes: Advantages and Disadvantages
Figure 3.4 Critical Design Parameters of Prefilled Syringes
Figure 3.5 Prefilled Syringe Manufacturing Process
Figure 4.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Figure 4.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 4.3 Prefilled Syringes: Distribution by Type of Needle System
Figure 4.4 Prefilled Syringes: Distribution by Device Capacity
Figure 4.5 Prefilled Syringe Developers: Distribution by Year of Establishment
Figure 4.6 Prefilled Syringe Developers: Distribution by Company Size
Figure 4.7 Prefilled Syringe Developers: Distribution by Geographical Location of Headquarters
Figure 4.8 Prefilled Syringe Developers: Distribution by Geographical Location of Manufacturing Facilities
Figure 4.9 Evolution of Prefilled Syringes
Figure 5.1 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
Figure 5.2 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
Figure 6.1 BD Medical: Annual Revenues, FY 2011 - FY 2018 (USD Billion)
Figure 6.2 BD Medical: Revenue Distribution by Sub-Segments, FY 2018 (USD Billion)
Figure 6.3 West Pharmaceutical: Annual Revenues, 2011 - H1 2019 (USD Million)
Figure 6.4 West Pharmaceutical: Revenue Distribution by Business Segments, 2018 (USD Million)
Figure 6.5 West Pharmaceutical: Revenue Distribution by Region, 2018 (USD Million)
Figure 6.6 Gerresheimer: Annual Revenues, 2011 - H1 2019 (EUR Million)
Figure 6.7 Gerresheimer: Revenue Distribution by Business Divisions, FY 2018 (EUR Million)
Figure 6.8 Gerresheimer: Revenue Distribution by Region, FY 2018 (EUR Million)
Figure 6.9 SCHOTT: Annual Revenues, FY 2013 - FY 2018 (EUR Million)
Figure 6.10 SCHOTT: Revenue Distribution by Geography, FY 2018 (EUR Million)
Figure 6.11 Nipro Corporation: Annual Revenues, FY 2012 – FY 2019 (JPY Billion)
Figure 6.12 Nipro Corporation: Revenue Distribution by Business Divisions, FY 2019 (JPY Billion)
Figure 6.13 Nipro Corporation: Revenue Distribution by Region, FY 2019 (JPY Billion)
Figure 6.14 Weigao: Annual Revenues, 2016-H12019 (RMB Billion)
Figure 6.15 Weigao: Revenue Distribution by Principle Products, H1 2019 (RMB Million)
Figure 6.16 Terumo: Annual Revenues, FY 2012 - FY 2019 (JPY Billion)
Figure 6.17 Terumo: Revenue Distribution by Business Divisions, FY 2018 (JPY Billion)
Figure 6.18 Terumo: Revenue Distribution by Region, FY 2018 (JPY Billion)
Figure 7.1 Worldwide Evolution in Healthcare Safety Legislation
Figure 8.1 Global Regulations Related to Prefilled Syringes
Figure 8.2 Approval Pathway for Combination Products in the US
Figure 8.3 Approval Pathway for Combination Products in Canada
Figure 8.4 Approval Pathway for Combination Products in China
Figure 9.1 Approved Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
Figure 9.2 Approved Prefilled Syringe Combination Products: Distribution by Approval Year
Figure 9.3 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
Figure 9.4 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
Figure 9.5 Approved Prefilled Syringes Combination Products: Distribution by Dose Strength
Figure 9.6 Approved Prefilled Syringes Combination Products: Distribution by Other Dosage Forms
Figure 9.7 Pipeline Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Figure 9.8 Pipeline Prefilled Syringes Combination Products: Distribution by Phase of Development
Figure 9.9 Pipeline Prefilled Syringes Combination Products: Distribution by Route of Administration
Figure 9.10 Approved Prefilled Syringes Combination Products: Distribution by Target Therapeutic Area
Figure 9.11 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
Figure 9.12 Prefilled Syringe Combination Product Developers: Distribution by Company Size
Figure 9.13 Prefilled Syringe Combination Product Developers: Distribution by Geographical Location of Headquarters
Figure 9.14 HUMIRA®: Approval Timeline (US, EU and Japan)
Figure 9.15 HUMIRA®: Approval Timeline for Different Dosage Forms (US and EU)
Figure 9.16 HUMIRA®: Annual Sales, 2003-Q3 2019 (USD Million)
Figure 9.17 Enbrel®: Approval Timeline (US and EU)
Figure 9.18 Enbrel®: Approval Timeline for Different Dosage Forms (US and EU)
Figure 9.19 Enbrel®: Annual Sales in the US and Canada, 2002-2018 (USD Million)
Figure 9.20 Enbrel®: Annual Sales outside US and Canada, 2010-2018 (USD Million)
Figure 12.1 Big Pharma Initiatives: Analysis by Therapeutic Area
Figure 12.2 Big Pharma Initiatives: Analysis by Autoimmune Disorders
Figure 12.3 Big Pharma Initiatives: Analysis by Infectious Diseases
Figure 12.4 Big Pharma Initiatives: Analysis by Neurological Disorders
Figure 12.5 Big Pharma Initiatives: Analysis by Oncologic Disorders
Figure 12.6 Big Pharma Initiatives: Analysis by Orthopedic Disorders
Figure 12.7 Big Pharma Initiatives: Analysis by Metabolic Disorders
Figure 12.8 Big Pharma Initiatives: Analysis by Inflammatory Disorders
Figure 12.9 Big Pharma Initiatives: Analysis by Other Disorders
Figure 12.10 Big Pharma Initiatives: Analysis by Type of Molecule
Figure 12.11 Big Pharma Initiatives: Analysis by Antibodies
Figure 12.12 Big Pharma Initiatives: Analysis by Proteins
Figure 12.13 Big Pharma Initiatives: Analysis by Vaccines
Figure 12.14 Big Pharma Initiatives: Analysis by Other Molecules
Figure 15.1 Prefilled Syringe Prices, 2019-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Figure 15.2 Global Prefilled Syringes Market, 2019-2030 (Million Units)
Figure 15.3 Global Prefilled Syringes Market, 2019-2030 (USD Million)
Figure 15.4 Prefilled Syringes Market: Distribution by Therapeutic Area, 2019-2030 (Million Units)
Figure 15.5 Prefilled Syringes Market: Distribution by Therapeutic Area, 2019-2030 (USD Million)
Figure 15.6 Prefilled Syringes Market: Share of Autoimmune Disorders, 2019-2030 (Million Units)
Figure 15.7 Prefilled Syringes Market: Share of Autoimmune Disorders, 2019-2030 (USD Million)
Figure 15.8 Prefilled Syringes Market: Share of Infectious Diseases, 2019-2030 (Million Units)
Figure 15.9 Prefilled Syringes Market: Share of Infectious Diseases, 2019-2030 (USD Million)
Figure 15.10 Prefilled Syringes Market: Share of Neurological Disorders, 2019-2030 (Million Units)
Figure 15.11 Prefilled Syringes Market: Share of Neurological Disorders, 2019-2030 (USD Million)
Figure 15.12 Prefilled Syringes Market: Share of Oncologic Disorders, 2019-2030 (Million Units)
Figure 15.13 Prefilled Syringes Market: Share of Oncologic Disorders, 2019-2030 (USD Million)
Figure 15.14 Prefilled Syringes Market: Share of Ophthalmic Diseases, 2019-2030 (Million Units)
Figure 15.15 Prefilled Syringes Market: Share of Ophthalmic Diseases, 2019-2030 (USD Million)
Figure 15.16 Prefilled Syringes Market: Share of Other Diseases, 2019-2030 (Million Units)
Figure 15.17 Prefilled Syringes Market: Share of Other Diseases, 2019-2030 (USD Million)
Figure 15.18 Global Prefilled Syringes Market: Distribution by Specialty Syringes, 2019-2030 (Million Units)
Figure 15.19 Global Prefilled Syringes Market: Distribution by Specialty Syringes, 2019-2030 (USD Million)
Figure 15.20 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, 2019-2030 (Million Units)
Figure 15.21 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, 2019-2030 (USD Million)
Figure 15.22 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, 2019-2030 (Million Units)
Figure 15.23 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, 2019-2030 (USD Million)
Figure 15.24 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, 2019-2030 (Million Units)
Figure 15.25 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, 2019-2030 (USD Million)
Figure 15.26 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, 2019-2030 (Million Units)
Figure 15.27 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, 2019-2030 (USD Million)
Figure 15.28 Global Prefilled Syringes Market: Share of Antibodies, 2019-2030 (Million Units)
Figure 15.29 Global Prefilled Syringes Market: Share of Antibodies, 2019-2030 (USD Million)
Figure 15.30 Global Prefilled Syringes Market: Share of Proteins, 2019-2030 (Million Units)
Figure 15.31 Global Prefilled Syringes Market: Share of Proteins, 2019-2030 (USD Million)
Figure 15.32 Global Prefilled Syringes Market: Share of Peptides, 2019-2030 (Million Units)
Figure 15.33 Global Prefilled Syringes Market: Share of Peptides, 2019-2030 (USD Million)
Figure 15.34 Global Prefilled Syringes Market: Share of Small Molecule, 2019-2030 (Million Units)
Figure 15.35 Global Prefilled Syringes Market: Share of Small Molecule, 2019-2030 (USD Million)
Figure 15.36 Global Prefilled Syringes Market: Share of Vaccines, 2019-2030 (Million Units)
Figure 15.37 Global Prefilled Syringes Market: Share of Vaccines, 2019-2030 (USD Million)
Figure 15.38 Global Prefilled Syringes Market: Distribution by Geography, 2019-2030 (Million Units)
Figure 15.39 Global Prefilled Syringes Market: Distribution by Geography, 2019-2030 (USD Million)
Figure 15.40 Global Prefilled Syringes Market: Distribution by North America, 2019-2030 (Million Units)
Figure 15.41 Global Prefilled Syringes Market: Distribution by North America, 2019-2030 (USD Million)
Figure 15.42 Global Prefilled Syringes Market: Distribution by Europe, 2019-2030 (Million Units)
Figure 15.43 Global Prefilled Syringes Market: Distribution by Europe, 2019-2030 (USD Million)
Figure 15.44 Global Prefilled Syringes Market: Distribution by Latin America, 2019-2030 (Million Units)
Figure 15.45 Global Prefilled Syringes Market: Distribution by Latin America, 2019-2030 (USD Million)
Figure 15.46 Global Prefilled Syringes Market: Distribution by Asia-Pacific, 2019-2030 (Million Units)
Figure 15.47 Global Prefilled Syringes Market: Distribution by Asia-Pacific, 2019-2030 (USD Million)
Figure 15.48 Global Prefilled Syringes Market: Distribution by Middle East and Africa, 2019-2030 (Million Units)
Figure 15.49 Global Prefilled Syringes Market: Distribution by Middle East and Africa, 2019-2030 (USD Million)
Figure 16.1 Diabetes: Country Wise Distribution of Prevalence and Mortality, 2017
Figure 16.2 FDA Approved Biologics, 2009-2019
Figure 16.3 Top Selling Biologics: Estimated Patent Expiry
Figure 17.1 SWOT Analysis
Figure 17.2 Prefilled Syringe Recalls: Distribution by Type of Concern, 2003-2019
Figure 17.1 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 18.1 AptarGroup: Annual Revenues, 2013 - H1 2019 (USD Billion)
Figure 18.2 Datwyler Group: Annual Revenues, 2013 - H12019 (CHF Million)
Figure 18.3 Sumitomo Rubber Industries: Annual Revenues, 2013 - H1 2019 (JPY Billion)
Figure 18.4 Sumitomo Rubber Industries: Revenue Distribution by Business Segment, 2018
Figure 19.1 Prefilled Syringe: Fill-Finish Process
Figure 19.2 Prefilled Syringe Fill-Finish Service Providers: Distribution by Year of Establishment
Figure 19.3 Prefilled Syringe Fill-Finish Service Providers: Distribution by Scale of Operation
Figure 19.4 Prefilled Syringe Fill-Finish Service Providers: Distribution by Geographical Location of Headquarters and Type of Drug Molecule
Figure 20.1 Elcam Medical: Products
Figure 20.2 Elcam Medical: Flexi-Q Autoinjectors
Figure 20.3 Owen Mumford: Cartridge-Based Injection Pens
Figure 20.4 Owen Mumford: Autoinjectors
Figure 20.5 SHL Medical: Product Portfolio
Figure 20.6 SHL Medical: Prefilled Syringe Based Autoinjectors
Figure 20.7 SHL Medical: Cartridge Based Autoinjectors
Figure 20.8 SHL Medical: Two-Step Autoinjectors
Figure 20.9 SHL Medical: Three-Step Autoinjectors
Figure 20.10 Union Medico: 45˚ Autoinjector Portfolio
Figure 20.11 Union Medico: Types of 45˚/R Autoinjector
Figure 20.12 Union Medico: Types of 90˚ Autoinjectors
Figure 20.13 Ypsomed: Cartridge Based Pen Injectors
Figure 20.14 Ypsomed: Cartridge Based Dual-Chamber Pen Injectors
Figure 20.15 Ypsomed: Prefilled Syringe or Cartridge Based Autoinjectors
Table 3.1 List of Drug Products Available in Prefilled Syringes
Table 3.2 Components of Prefilled Syringes
Table 3.3 Classification of Prefilled Syringes
Table 3.4 Advantages of Glass as Barrel Fabrication Material
Table 3.5 Glass Barrel Prefilled Syringe Recalls
Table 3.6 Advantages of Plastic Polymers as Barrel Fabrication Material
Table 3.7 Steps Involved in Filling of Prefilled Syringes
Table 4.1 Prefilled Syringes: List of Devices
Table 4.2 Prefilled Syringes: List of Developers
Table 6.1 Key Manufacturers of Prefilled Syringes
Table 6.2 Becton Dickinson: Recent Developments and Future Outlook
Table 6.3 West Pharmaceutical: Features of Daikyo Crystal Zenith Prefilled Syringe
Table 6.5 Gerresheimer: Features of Gx Glass Prefilled Syringe
Table 6.6 Gerresheimer: Features of ClearJect Prefilled Syringe
Table 6.8 Ompi: Features of EZ-Fill Fina Prefilled Syringe
Table 6.9 Ompi: Features of EZ-Fill Nexa Prefilled Syringe
Table 6.10 Ompi: Features of EZ-Fill Alba Prefilled Syringe
Table 6.12 SCHOTT: Features of syriQ Prefilled Syringe
Table 6.13 SCHOTT: Features of TopPac Prefilled Syringe
Table 6.15 Nipro: Features of Prefilled Syringe,
Table 6.17 Weigao: Features of WeGo Glass Prefilled Syringe,
Table 6.18 Taisei Kako: Features of VF-Syringes
Table 6.19 Taisei Kako: Features of SIN-Syringes
Table 6.20 Taisei Kako: Features of ClearJect Prefilled Syringes,
Table 6.21 Taisei Kako: Features of FULJECT Passive Type Syringes
Table 6.22 Shandong Zibo: Features of Prefilled Syringes
Table 6.23 Vetter Pharma: Features of Lyo-Ject Glass Prefilled Syringe
Table 7.1 Add-On Safety Device Manufacturers
Table 7.2 Integrated Prefilled Safety Device Manufacturers
Table 8.1 US FDA Center for Drug and Device Approval
Table 8.2 Regulatory Review Timelines in the US
Table 8.3 Regulatory Bodies in EU5 Countries
Table 8.4 Regulatory Review Timelines in Saudi Arabia
Table 9.1 Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2019
Table 9.2 Prefilled Syringe Combination Products: List of Pipeline Drugs, 2013-2019
Table 9.3 Prefilled Syringe Combination Products: List of Developers
Table 10.1 Leading Drugs for Autoimmune Disorders
Table 10.2 Drugs for Autoimmune Diseases Available in Prefilled Syringes
Table 10.3 Drugs for Autoimmune Diseases Available in Prefilled Format: Information on Patent Expiry and Biosimilars
Table 10.4 Leading Antiviral Drugs
Table 10.5 Antiviral Drugs Available in Prefilled Syringes
Table 10.6 Antiviral Drugs Available in Prefilled Format: Information on Patent Expiry and Biosimilars
Table 10.7 Popular Vaccines
Table 10.8 Vaccines Available in Prefilled Syringes
Table 10.9 Leading Drugs for Multiple Sclerosis
Table 10.10 Drugs for Multiple Sclerosis Available in Prefilled Syringes
Table 10.11 Drugs for Multiple Sclerosis Available in Prefilled Format: Information on Patent Expiry and Biosimilars
Table 10.12 Leading Drugs for Diabetes
Table 10.13 Drugs for Diabetes Available in Prefilled Insulin Pen
Table 10.14 Drugs for Diabetes Available in Prefilled Format: Information on Patent Expiry and Biosimilars
Table 11.1 Approved Molecules: Most Likely Candidates for Delivery via Prefilled Syringes
Table 11.2 Approved Molecules: Likely Candidates for Delivery via Prefilled Syringes
Table 11.3 Approved Molecules: Less Likely Candidates for Delivery via Prefilled Syringes
Table 11.4 Approved Molecules: Unlikely Candidates for Delivery via Prefilled Syringes
Table 11.5 Pipeline Drug Candidates: Most Likely Candidates for Delivery via Prefilled Syringes
Table 11.6 Pipeline Drug Candidates: Likely Candidates for Delivery via Prefilled Syringes
Table 11.7 Pipeline Drug Candidates: Less Likely Candidates for Delivery via Prefilled Syringes
Table 11.8 Pipeline Drug Candidates: Unlikely Candidates for Delivery via Prefilled Syringes
Table 11.9 Opportunities in North America: Most Likely Partners for Prefilled Syringe Combination Product Development
Table 11.10 Opportunities in North America: Likely Partners for Prefilled Syringe Combination Product Development
Table 11.12 Opportunities in North America: Less Likely Partners for Prefilled Syringe Combination Product Development
Table 11.13 Opportunities in North America: Unlikely Partners for Prefilled Syringe Combination Product Development
Table 11.14 Opportunities in Europe: Most Likely Partners for Prefilled Syringe Combination Product Development
Table 11.15 Opportunities in Europe: Likely Partners for Prefilled Syringe Combination Product Development
Table 11.16 Opportunities in Europe: Less Likely Partners for Prefilled Syringe Combination Product Development
Table 11.17 Opportunities in Europe: Unlikely Partners for Prefilled Syringe Combination Product Development
Table 11.18 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners Prefilled Syringe Combination Product Development
Table 11.19 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Prefilled Syringe Combination Product Development
Table 11.20 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners Prefilled Syringe Combination Product Development
Table 11.21 Opportunities in Asia-Pacific and Rest of the World: Unlikely Partners Prefilled Syringe Combination Product Development
Table 13.1 Prefilled Flush Syringes Available in the Market
Table 13.2 Drugs Available in Prefilled Diluent Syringes
Table 13.3 Contrast Agents Available in Prefilled Syringes
Table 14.1 Dual / Multi-Chamber Prefilled Syringes
Table 14.2 Approved Drugs in Dual / Multi-Chamber Prefilled Syringes
Table 16.1 Fraction of Global Population above 60 years (in Millions), 2017, 2030 and 2050
Table 16.2 Autoinjector Approvals, 2016-2019
Table 16.3 Marketed Autoinjectors / Pen Injectors with Prefilled Syringes
Table 18.1 Prefilled Syringe Component Manufacturers: List of Elastomeric Container Closure Providers
Table 18.2 Elastomeric Container Closure Providers for Prefilled Syringes: List of Companies Profiled
Table 18.3 AptarGroup: Company Overview
Table 18.4 Aptar Pharma: Product Details
Table 18.5 AptarGroup: Recent Developments and Future Outlook
Table 18.6 West Pharmaceutical: Company Overview
Table 18.7 West Pharmaceutical: Product Details
Table 18.8 Datwyler Sealing Solutions (Datwyler Group): Company Overview
Table 18.9 Datwyler Sealing Solutions (Datwyler Group): Product Details
Table 18.10 Datwyler Sealing Solutions (Datwyler Group): Recent Developments and Future Outlook
Table 18.11 Lonstroff: Company Overview
Table 18.12 Lonstroff: Product Details
Table 18.13 Sumitomo Rubber Industries: Company Overview
Table 18.14 Sumitomo Rubber Industries: Recent Developments and Future Outlook
Table 18.15 Ompi (Stevanato Group): Company Overview
Table 18.16 Ompi (Stevanato Group): Product Details
Table 18.17 Jiangsu Hualan Pharmaceutical New Material: Company Overview
Table 18.18 Jiangsu Hualan Pharmaceutical New Material: Product Details
Table 19.1 List of Fill-Finish Service Providers
Table 20.1 List of Autoinjector Devices Using Prefilled Syringes
Table 20.2 Features of Autoject® Flex Variants
Table 22.1 Oval Medical Technologies: Company Snapshot
Table 22.2 Intas Pharmaceuticals: Company Snapshot
Table 22.3 IDT Biologika: Company Snapshot
Table 22.4 West Pharmaceutical: Company Snapshot
Table 22.5 Lonstroff: Company Snapshot
Table 23.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Table 23.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 23.3 Prefilled Syringes: Distribution by Type of Needle System
Table 23.4 Prefilled Syringes: Distribution by Device Capacity
Table 23.5 Prefilled Syringe Developers: Distribution by Year of Establishment
Table 23.6 Prefilled Syringe Developers: Distribution by Company Size
Table 23.7 Prefilled Syringe Developers: Distribution by Geographical Location of Headquarters
Table 23.8 BD Medical: Annual Revenues, FY 2011 - FY 2018 (USD Billion)
Table 23.9 BD Medical: Revenue Distribution by Sub-Segments, FY 2018 (USD Billion)
Table 23.10 West Pharmaceutical: Annual Revenues, 2011 - H1 2019 (USD Million)
Table 23.11 West Pharmaceutical: Revenue Distribution by Business Segments, 2018 (USD Million)
Table 23.12 West Pharmaceutical: Revenue Distribution by Region, 2018 (USD Million)
Table 23.13 Gerresheimer: Annual Revenues, 2011 - H1 2019 (EUR Million)
Table 23.14 Gerresheimer: Revenue Distribution by Business Divisions, FY 2018 (EUR Million)
Table 23.15 Gerresheimer: Revenue Distribution by Region, FY 2018 (EUR Million)
Table 23.16 SCHOTT: Annual Revenues, FY 2013 - FY 2018 (EUR Million)
Table 23.17 SCHOTT: Revenue Distribution by Geography, FY 2018 (EUR Million)
Table 23.18 Nipro Corporation: Annual Revenues, FY 2012 – FY 2019 (JPY Billion)
Table 23.19 Nipro Corporation: Revenue Distribution by Business Divisions, FY 2019 (JPY Billion)
Table 23.20 Nipro Corporation: Revenue Distribution by Region, FY 2019 (JPY Billion)
Table 23.21 Weigao: Annual Revenues, 2016-H12019 (RMB Billion)
Table 23.22 Weigao: Revenue Distribution by Principle Products, H1 2019 (RMB Million)
Table 23.23 Terumo: Annual Revenues, FY 2012 - FY 2019 (JPY Billion)
Table 23.24 Terumo: Revenue Distribution by Business Divisions, FY 2018 (JPY Billion)
Table 23.25 Terumo: Revenue Distribution by Region, FY 2018 (JPY Billion)
Table 23.26 Approved Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
Table 23.27 Approved Prefilled Syringe Combination Products: Distribution by Approval Year
Table 23.28 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
Table 23.29 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
Table 23.30 Approved Prefilled Syringes Combination Products: Distribution by Dose Strength
Table 23.31 Approved Prefilled Syringes Combination Products: Distribution by Other Dosage Forms
Table 23.32 Pipeline Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Table 23.33 Pipeline Prefilled Syringes Combination Products: Distribution by Phase of Development
Table 23.34 Pipeline Prefilled Syringes Combination Products: Distribution by Route of Administration
Table 23.35 Approved Prefilled Syringes Combination Products: Distribution by Target Therapeutic Area
Table 23.36 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
Table 23.37 Prefilled Syringe Combination Product Developers: Distribution by Company Size
Table 23.38 Prefilled Syringe Combination Product Developers: Distribution by Geographical Location of Headquarters
Table 23.39 HUMIRA®: Annual Sales, 2003-Q3 2019 (USD Million)
Table 23.40 Enbrel®: Annual Sales in the US and Canada, 2002-2018 (USD Million)
Table 23.41 Enbrel®: Annual Sales outside US and Canada, 2010-2018 (USD Million)
Table 23.42 Prefilled Syringe Prices, 2019-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Table 23.43 Global Prefilled Syringes Market, Conservative Scenario, 2019-2030 (Million Units)
Table 23.44 Global Prefilled Syringes Market, Base Scenario, 2019-2030 (Million Units)
Table 23.45 Global Prefilled Syringes Market, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.46 Global Prefilled Syringes Market, Conservative Scenario, 2019-2030 (USD Million)
Table 23.47 Global Prefilled Syringes Market, Base Scenario, 2019-2030 (USD Million)
Table 23.48 Global Prefilled Syringes Market, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.49 Prefilled Syringes Market: Distribution by Therapeutic Area, Conservative Scenario, 2019-2030 (Million Units)
Table 23.50 Prefilled Syringes Market: Distribution by Therapeutic Area, Base Scenario, 2019-2030 (Million Units)
Table 23.51 Prefilled Syringes Market: Distribution by Therapeutic Area, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.52 Prefilled Syringes Market: Distribution by Therapeutic Area, Conservative Scenario, 2019-2030 (USD Million)
Table 23.53 Prefilled Syringes Market: Distribution by Therapeutic Area, Base Scenario, 2019-2030 (USD Million)
Table 23.54 Prefilled Syringes Market: Distribution by Therapeutic Area, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.55 Prefilled Syringes Market: Share of Autoimmune Disorders, Conservative Scenario, 2019-2030 (Million Units)
Table 23.56 Prefilled Syringes Market: Share of Autoimmune Disorders, Base Scenario, 2019-2030 (Million Units)
Table 23.57 Prefilled Syringes Market: Share of Autoimmune Disorders, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.58 Prefilled Syringes Market: Share of Autoimmune Disorders, Conservative Scenario, 2019-2030 (USD Million)
Table 23.59 Prefilled Syringes Market: Share of Autoimmune Disorders, Base Scenario, 2019-2030 (USD Million)
Table 23.60 Prefilled Syringes Market: Share of Autoimmune Disorders, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.61 Prefilled Syringes Market: Share of Infectious Diseases, Conservative Scenario, 2019-2030 (Million Units)
Table 23.62 Prefilled Syringes Market: Share of Infectious Diseases, Base Scenario, 2019-2030 (Million Units)
Table 23.63 Prefilled Syringes Market: Share of Infectious Diseases, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.64 Prefilled Syringes Market: Share of Infectious Diseases, Conservative Scenario, 2019-2030 (USD Million)
Table 23.65 Prefilled Syringes Market: Share of Infectious Diseases, Base Scenario, 2019-2030 (USD Million)
Table 23.66 Prefilled Syringes Market: Share of Infectious Diseases, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.67 Prefilled Syringes Market: Share of Neurological Disorders, Conservative Scenario, 2019-2030 (Million Units)
Table 23.68 Prefilled Syringes Market: Share of Neurological Disorders, Base Scenario, 2019-2030 (Million Units)
Table 23.69 Prefilled Syringes Market: Share of Neurological Disorders, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.70 Prefilled Syringes Market: Share of Neurological Disorders, Conservative Scenario, 2019-2030 (USD Million)
Table 23.71 Prefilled Syringes Market: Share of Neurological Disorders, Base Scenario, 2019-2030 (USD Million)
Table 23.72 Prefilled Syringes Market: Share of Neurological Disorders, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.73 Prefilled Syringes Market: Share of Oncologic Disorders, Conservative Scenario, 2019-2030 (Million Units)
Table 23.74 Prefilled Syringes Market: Share of Oncologic Disorders, Base Scenario, 2019-2030 (Million Units)
Table 23.75 Prefilled Syringes Market: Share of Oncologic Disorders, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.76 Prefilled Syringes Market: Share of Oncologic Disorders, Conservative Scenario, 2019-2030 (USD Million)
Table 23.77 Prefilled Syringes Market: Share of Oncologic Disorders, Base Scenario, 2019-2030 (USD Million)
Table 23.78 Prefilled Syringes Market: Share of Oncologic Disorders, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.79 Prefilled Syringes Market: Share of Ophthalmic Diseases, Conservative Scenario, 2019-2030 (Million Units)
Table 23.80 Prefilled Syringes Market: Share of Ophthalmic Diseases, Base Scenario, 2019-2030 (Million Units)
Table 23.81 Prefilled Syringes Market: Share of Ophthalmic Diseases, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.82 Prefilled Syringes Market: Share of Ophthalmic Diseases, Conservative Scenario, 2019-2030 (USD Million)
Table 23.83 Prefilled Syringes Market: Share of Ophthalmic Diseases, Base Scenario, 2019-2030 (USD Million)
Table 23.84 Prefilled Syringes Market: Share of Ophthalmic Diseases, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.85 Prefilled Syringes Market: Share of Other Diseases, Conservative Scenario, 2019-2030 (Million Units)
Table 23.86 Prefilled Syringes Market: Share of Other Diseases, Base Scenario, 2019-2030 (Million Units)
Table 23.87 Prefilled Syringes Market: Share of Other Diseases, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.88 Prefilled Syringes Market: Share of Other Diseases, Conservative Scenario, 2019-2030 (USD Million)
Table 23.89 Prefilled Syringes Market: Share of Other Diseases, Base Scenario, 2019-2030 (USD Million)
Table 23.90 Prefilled Syringes Market: Share of Other Diseases, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.91 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Conservative Scenario, 2019-2030 (Million Units)
Table 23.92 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Base Scenario, 2019-2030 (Million Units)
Table 23.93 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.94 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Conservative Scenario, 2019-2030 (USD Million)
Table 23.95 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Base Scenario, 2019-2030 (USD Million)
Table 23.96 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Base Scenario, 2019-2030 (USD Million)
Table 23.97 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2019-2030 (Million Units)
Table 23.98 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2019-2030 (Million Units)
Table 23.99 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.100 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2019-2030 (USD Million)
Table 23.101 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2019-2030 (USD Million)
Table 23.102 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.103 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2019-2030 (Million Units)
Table 23.104 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2019-2030 (Million Units)
Table 23.105 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.106 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2019-2030 (USD Million)
Table 23.107 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2019-2030 (USD Million)
Table 23.108 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.109 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2019-2030 (Million Units)
Table 23.110 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Base Scenario, 2019-2030 (Million Units)
Table 23.111 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.112 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2019-2030 (USD Million)
Table 23.113 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Base Scenario, 2019-2030 (USD Million)
Table 23.114 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.115 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2019-2030 (Million Units)
Table 23.116 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2019-2030 (Million Units)
Table 23.117 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.118 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2019-2030 (USD Million)
Table 23.119 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2019-2030 (USD Million)
Table 23.120 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.121 Global Prefilled Syringes Market: Share of Antibodies, Conservative Scenario, 2019-2030 (Million Units)
Table 23.122 Global Prefilled Syringes Market: Share of Antibodies, Base Scenario, 2019-2030 (Million Units)
Table 23.123 Global Prefilled Syringes Market: Share of Antibodies, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.124 Global Prefilled Syringes Market: Share of Antibodies, Conservative Scenario, 2019-2030 (USD Million)
Table 23.125 Global Prefilled Syringes Market: Share of Antibodies, Base Scenario, 2019-2030 (USD Million)
Table 23.126 Global Prefilled Syringes Market: Share of Antibodies, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.127 Global Prefilled Syringes Market: Share of Proteins, Conservative Scenario, 2019-2030 (Million Units)
Table 23.128 Global Prefilled Syringes Market: Share of Proteins, Base Scenario, 2019-2030 (Million Units)
Table 23.129 Global Prefilled Syringes Market: Share of Proteins, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.130 Global Prefilled Syringes Market: Share of Proteins, Conservative Scenario, 2019-2030 (USD Million)
Table 23.131 Global Prefilled Syringes Market: Share of Proteins, Base Scenario, 2019-2030 (USD Million)
Table 23.132 Global Prefilled Syringes Market: Share of Proteins, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.133 Global Prefilled Syringes Market: Share of Peptides, Conservative Scenario, 2019-2030 (Million Units)
Table 23.134 Global Prefilled Syringes Market: Share of Peptides, Base Scenario, 2019-2030 (Million Units)
Table 23.135 Global Prefilled Syringes Market: Share of Peptides, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.136 Global Prefilled Syringes Market: Share of Peptides, Conservative Scenario, 2019-2030 (USD Million)
Table 23.137 Global Prefilled Syringes Market: Share of Peptides, Base Scenario, 2019-2030 (USD Million)
Table 23.138 Global Prefilled Syringes Market: Share of Peptides, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.139 Global Prefilled Syringes Market: Share of Small Molecule, Conservative Scenario, 2019-2030 (Million Units)
Table 23.140 Global Prefilled Syringes Market: Share of Small Molecule, Base Scenario, 2019-2030 (Million Units)
Table 23.141 Global Prefilled Syringes Market: Share of Small Molecule, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.142 Global Prefilled Syringes Market: Share of Small Molecule, Conservative Scenario, 2019-2030 (USD Million)
Table 23.143 Global Prefilled Syringes Market: Share of Small Molecule, Base Scenario, 2019-2030 (USD Million)
Table 23.144 Global Prefilled Syringes Market: Share of Small Molecule, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.145 Global Prefilled Syringes Market: Share of Vaccines, Conservative Scenario, 2019-2030 (Million Units)
Table 23.146 Global Prefilled Syringes Market: Share of Vaccines, Base Scenario, 2019-2030 (Million Units)
Table 23.147 Global Prefilled Syringes Market: Share of Vaccines, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.148 Global Prefilled Syringes Market: Share of Vaccines, Conservative Scenario, 2019-2030 (USD Million)
Table 23.149 Global Prefilled Syringes Market: Share of Vaccines, Base Scenario, 2019-2030 (USD Million)
Table 23.150 Global Prefilled Syringes Market: Share of Vaccines, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.151 Global Prefilled Syringes Market: Distribution by Geography, Conservative Scenario, 2019-2030 (Million Units)
Table 23.152 Global Prefilled Syringes Market: Distribution by Geography, Base Scenario, 2019-2030 (Million Units)
Table 23.153 Global Prefilled Syringes Market: Distribution by Geography, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.154 Global Prefilled Syringes Market: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 23.155 Global Prefilled Syringes Market: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 23.156 Global Prefilled Syringes Market: Distribution by Geography, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.157 Global Prefilled Syringes Market: Distribution by North America, Conservative Scenario, 2019-2030 (Million Units)
Table 23.158 Global Prefilled Syringes Market: Distribution by North America, Base Scenario, 2019-2030 (Million Units)
Table 23.159 Global Prefilled Syringes Market: Distribution by North America, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.160 Global Prefilled Syringes Market: Distribution by North America, Conservative Scenario, 2019-2030 (USD Million)
Table 23.161 Global Prefilled Syringes Market: Distribution by North America, Base Scenario, 2019-2030 (USD Million)
Table 23.162 Global Prefilled Syringes Market: Distribution by North America, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.163 Global Prefilled Syringes Market: Distribution by Europe, Conservative Scenario, 2019-2030 (Million Units)
Table 23.164 Global Prefilled Syringes Market: Distribution by Europe, Base Scenario, 2019-2030 (Million Units)
Table 23.165 Global Prefilled Syringes Market: Distribution by Europe, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.166 Global Prefilled Syringes Market: Distribution by Europe, Conservative Scenario, 2019-2030 (USD Million)
Table 23.167 Global Prefilled Syringes Market: Distribution by Europe, Base Scenario, 2019-2030 (USD Million)
Table 23.168 Global Prefilled Syringes Market: Distribution by Europe, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.169 Global Prefilled Syringes Market: Distribution by Latin America, Conservative Scenario, 2019-2030 (Million Units)
Table 23.170 Global Prefilled Syringes Market: Distribution by Latin America, Base Scenario, 2019-2030 (Million Units)
Table 23.171 Global Prefilled Syringes Market: Distribution by Latin America, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.172 Global Prefilled Syringes Market: Distribution by Latin America, Conservative Scenario, 2019-2030 (USD Million)
Table 23.173 Global Prefilled Syringes Market: Distribution by Latin America, Base Scenario, 2019-2030 (USD Million)
Table 23.174 Global Prefilled Syringes Market: Distribution by Latin America, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.175 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Conservative Scenario, 2019-2030 (Million Units)
Table 23.176 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Base Scenario, 2019-2030 (Million Units)
Table 23.177 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.178 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Conservative Scenario, 2019-2030 (USD Million)
Table 23.179 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Base Scenario, 2019-2030 (USD Million)
Table 23.180 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.181 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Conservative Scenario, 2019-2030 (Million Units)
Table 23.182 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Base Scenario, 2019-2030 (Million Units)
Table 23.183 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.184 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Conservative Scenario, 2019-2030 (USD Million)
Table 23.185 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Base Scenario, 2019-2030 (USD Million)
Table 23.186 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Optimistic Scenario, 2019-2030 (USD Million)
Table 23.187 FDA Approved Biologics, 2009-2019
Table 23.188 Aptar Group: Annual Revenues, 2013 - H1 2019 (USD Billion)
Table 23.189 Datwyler Group: Annual Revenues, 2013 - H12019 (CHF Million)
Table 23.190 Sumitomo Rubber Industries: Annual Revenues, 2013 - H1 2019 (JPY Billion)
Table 23.191 Sumitomo Rubber Industries: Revenue Distribution by Business Segment, 2018
Table 23.192 Prefilled Syringe Fill-Finish Service Providers: Distribution by Year of Establishment
Table 23.193 Prefilled Syringe Fill-Finish Service Providers: Distribution by Scale of Operation
Table 23.194 Prefilled Syringe Fill-Finish Service Providers: Distribution by Geographical Location of Headquarters and Type of Drug Molecule
The following companies and organizations have been mentioned in the report.
Discounts available for multiple report purchases
sales@rootsanalysis.com
.png)
.jpg)
.png)
.png)
.jpg)
.jpg)
.jpg)
